Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities lawsuit

Fractyl Health Revita Securities Fraud Class Action

Analysis based on 80 articles · First reported Aug 22, 2026 · Last updated Sep 22, 2026

Sentiment
-20
Attention
2
Articles
80
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The lawsuit and the sharp share-price collapse keep negative pressure on Fractyl Health's equity and raise its litigation and reputational risk, while the case is largely idiosyncratic and unlikely to move broad market indices. It reinforces scrutiny of clinical-trial disclosure practices across small-cap biotech, a modest sentiment negative for the sector.

biotechnology pharmaceuticals legal services

Multiple investor-rights law firms have filed and are publicizing a securities class action against Fractyl Health, Inc. (NASDAQ: GUTS) and certain of its officers in the United States — United States District Court for the Southern District of New York. The complaint alleges that during the Class Period of January 13, 2025 to January 29, 2026, defendants made materially false and misleading statements about the company's Revita DMR System and the REMAIN-1 Midpoint Cohort. Specifically, the suit claims Revita was less effective than represented and that operational issues at one of the six REMAIN-1 Midpoint Cohort clinical sites compromised the integrity of efficacy results, overstating Revita's clinical, regulatory, and commercial prospects. On January 29, 2026, Fractyl reported six-month data showing 4.5% weight regain in Revita-treated patients versus 7.5% in the sham arm, and CEO Harith Rajagopalan reportedly attributed part of the disappointing result to a site with higher-than-expected regain across both arms. Fractyl shares reportedly fell about 68% to $0.58 on January 29, 2026, and a further 21% to $0.46 on January 30, 2026. Law firms including Bronstein, Gewirtz & Grossman, LLC, Glancy Prongay & Murray, Robbins LLP, Levi & Korsinsky, and the Law Offices of Frank R. Cruz are soliciting investors, with an October 20, 2026 lead plaintiff deadline. Analysts at Canaccord Genuity and Morgan Stanley have weighed in, with Morgan Stanley reportedly cutting its Revita probability of success from 50% to 35% and its price target from $8.00 to $2.00.

100 Robbins LLP filed class action Fractyl Health
97 Fractyl Health reported
95 Fractyl Health disclosed disappointing clinical data
92 Levi & Korsinsky filed class action Fractyl Health
90 Fractyl Health issued press release
90 Morgan Stanley downgraded stock Fractyl Health
80 Harith Rajagopalan blamed study site issues
80 Fractyl Health priced public offering
80 Glancy Prongay & Murray filed securities fraud class action Fractyl Health
80 Fractyl Health reported three-month data
70 The Law Offices of Frank R. Cruz announced securities fraud investigation Fractyl Health
70 Fractyl Health priced public offering
+ 13 more actions View on Dashboard
stock
The defendant company at the center of the securities class action; the fraud allegations and the roughly 75% cumulative stock decline from the class-period high severely damage its market credibility and financing prospects.
Importance 100.0 Sentiment -70.0
per
Fractyl CEO named as a defendant; his conference-call comments on the outlier REMAIN-1 site are central to the alleged misleading disclosures.
Importance 60.0 Sentiment -60.0
priv
The The Law Offices of Frank R. Cruz is involved in the securities fraud investigation and class action against Fractyl Health, representing investor interests.
Importance 50.0 Sentiment 10.0
priv
Lead publicizing firm that announced the class action and is soliciting Fractyl investors to join the case.
Importance 45.0 Sentiment 5.0
priv
Firm behind SueWallSt that detailed the alleged clinical-site execution failures and the stock decline in its investor alerts.
Importance 35.0 Sentiment 5.0
priv
Investor-rights firm reminding shareholders of the October 20, 2026 lead plaintiff deadline in the Fractyl action.
Importance 35.0 Sentiment 5.0
priv
Shareholder rights firm informing investors that a class action was filed on behalf of Fractyl purchasers during the Class Period.
Importance 30.0 Sentiment 5.0
per
Founding partner of Bronstein, Gewirtz & Grossman, LLC and the contact attorney promoting the Fractyl class action.
Importance 25.0 Sentiment 5.0
per
Levi & Korsinsky attorney and SueWallSt contact raising questions about the integrity of the REMAIN-1 Midpoint Cohort data.
Importance 25.0 Sentiment 5.0
stock
Analyst that reportedly cut its Revita probability of success from 50% to 35% and its price target from $8.00 to $2.00 after the data disclosure.
Importance 25.0 Sentiment 0.0
per
Aaron Dumas, Jr. is an attorney at Robbins LLP who is listed as a contact for investors seeking information about the class action. His role is administrative and does not directly affect the event's outcome.
Importance 20.0 Sentiment 0.0
per
Brian J. Robbins is the founding partner of Robbins LLP and is quoted in the press release. His involvement is limited to providing commentary on the case.
Importance 20.0 Sentiment 0.0
govactor
Court where the Fractyl securities class action was filed under the Private Securities Litigation Reform Act of 1995.
Importance 20.0 Sentiment 0.0
stock
Analyst firm whose post-market report attributed the outlier site's variability to a less robust diet and lifestyle counseling program.
Importance 20.0 Sentiment 0.0
The Law Offices of Frank R. Cruz co-plaintiffs ↔ Bronstein, Gewirtz & Grossman, LLC The Law Offices of Frank R. Cruz frequently acts as co-plaintiff with Bronstein, Gewirtz & Grossman in securities class
The Law Offices of Frank R. Cruz co-counsel ↔ Glancy Prongay & Murray The Law Offices of Frank R. Cruz frequently acts as co-counsel or pursues parallel class-action lawsuits with Glancy Pro
The Law Offices of Frank R. Cruz competitor ↔ Robbins LLP The Law Offices of Frank R. Cruz and Robbins LLP are direct competitors, often filing parallel securities class action l
Bronstein, Gewirtz & Grossman, LLC co-counsel ↔ Glancy Prongay & Murray Bronstein, Gewirtz & Grossman, LLC frequently acts as co-counsel with Glancy Prongay & Murray in various securities clas
Bronstein, Gewirtz & Grossman, LLC co-counsel ↔ Robbins LLP Bronstein, Gewirtz & Grossman, LLC frequently acts as co-counsel or co-solicitor with Robbins LLP in various securities
Levi & Korsinsky competitor ↔ Robbins LLP Levi & Korsinsky and Robbins LLP are both shareholder rights law firms that frequently compete for clients and lead plai
+ 6 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.